doxycycline acute bronchitis

<img class="aligncenter" src="https://scx1.b-cdn.net/csz/news/800a/2022/scientists-develop-a-n-7.jpg"
alt="Scientists develop a new non-opioid pain killer with fewer side effects"
title="BnOCPA is a potent analgesic without causing sedation or motor impairment. a BnOCPA did not induce sedation or affect motor function when injected intraperitoneally (IP; 10 µg kg⁻¹) or intravenously (IV; 10 or 25 µg kg⁻¹). In contrast, morphine caused sedation and motor impairment (15 mg kg⁻¹ subcutaneously, SC). Saline (Veh, SC) did not affect rotarod performance. Data points (mean ± SEM; n = 6 for each compound) are normalized to pre-dose performance and are offset for clarity. b, c BnOCPA alleviates mechanical allodynia in neuropathic pain when administered b via an intrathecal (IT) or c IV route. Pre-surgery (pre-surg) animals had similar sensitivity to tactile stimulation as assessed by von Frey hair stimulation. Spinal nerve ligation caused hypersensitivity to touch (mechanical allodynia) at 1 week after surgery as evidenced by the reduction in the tactile pressure necessary to elicit paw withdrawal (paw withdrawal threshold; PWT). PWT reaches a similar nadir across all groups prior to the vehicle or BnOCPA infusion (pre-dose). Administration of BnOCPA significantly increased PWT in the limb ipsilateral to the site of injury in a dose-dependent manner (one-way ANOVA (pre-dose, 1, naproxen patient teaching 2 and 4 hrs) for IT BnOCPA F(3,88) = 21.9, P = 1.10 × 10⁻¹⁰; for IV BnOCPA F(3,92) =18.1, P = 2.70 × 10⁻⁹). Fisher LSD post hoc comparisons showed significant differences at: IT 1 nmol at 1 and 2 hrs, P = 0.001 and 4.16 × 10⁻⁵, respectively, and 3 nmol at 1, 2 and 4 hrs, P = 9.52 × 10⁻¹¹, 1.42 × 10⁻¹¹ and 1.41 × 10⁻⁸, respectively; IV 3 µg kg⁻¹ at 1, 2 and 4 hrs, P = 0.044, 0.008 and 0.019, respectively, and 10 µg kg⁻¹ at 1, 2 and 4 hrs, P = 1.37 × 10⁻⁸, 6.81 × 10⁻¹⁴ and 3.23 × 10⁻4, respectively. b, c n = 6 per treatment, except for 1 nmol BnOCPA, n = 5. d The analgesic effects of BnOCPA (6 µg kg⁻¹ IV) were prevented by the A1R antagonist DPCPX (1 mg kg⁻¹ IP), but not the A3R-selective antagonist MRS1523 (2 mg kg⁻¹ IP). Post hoc LSD comparisons across all four groups and four-time points (pre-dose, 1, 2 and 4 hrs; F(15,116) = 26.8, P = 0) revealed that BnOCPA at 6 µg kg⁻¹ (IV) elicited significant analgesia compared to vehicle-treated animals at 1, 2, and 4 h post-dosing (P = 4.69 × 10⁻⁹, 3.50 × 10⁻¹⁶, 4.69 × 10⁻⁹, respectively), which persisted in the presence of the selective A3R antagonist MRS1523 over the same time period (P = 4.42 × 10⁻¹³, 3.38 × 10⁻¹⁴, 1.81 × 10⁻¹⁰, respectively). In contrast, the PWT in DPCPX-treated animals did not differ from those in the vehicle group (P = 0.872, 0.748, 0.453 at 1, 2, and 4 h, respectively). n = 11 for BnOCPA and vehicle groups; n = 6 for the DPCPX group and n = 5 for the MRS1523 group. Averaged data are presented as mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.02; ***, P < 0.001; ****, P < 0.0001. Credit: <i>Nature Communications</i> (2022). DOI: 10.1038/s41467-022-31652-2″ width=”800″ height=”529″>

A promising new non-opioid painkiller (analgesic) with potentially fewer side effects compared to other potent painkillers, has been discovered.

A team of scientists, co-led by researchers from the School of Life Sciences, University of Warwick, has investigated a compound called BnOCPA (benzyloxy-cyclopentyladenosine), found to be a potent and selective analgesic which is non-addictive in test model systems. BnOCPA also has a unique mode of action and potentially opens a new pipeline for the development of new analgesic drugs.

The research by the team at Warwick, together with colleagues at the University of Cambridge, University of Bern, Monash University, Coventry University and industrial collaborators, is published in Nature Communications in a paper titled “Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression.”

In the U.K. between one third and one half of the population report moderately to severely disabling chronic pain. Such pain has a negative impact on quality of life and many of the commonly used pain killers produce side effects. Opioid drugs, such as morphine and oxycodone, can lead to addiction and are dangerous in overdose. There is therefore an unmet need for new and potent pain killing drugs.

Many drugs act via proteins on the surface of cell surfaces that activate adapter molecules called G proteins. The activation of G proteins can lead to many cellular effects. BnOCPA is unique in that it only activates one type of G protein, leading to very selective effects and thus reducing potential side effects.

Dr. Mark Wall, from the School of Life Sciences at the University of Warwick, who led the research said, “The selectivity and potency of BnOCPA make it truly unique and we hope that with further research it will be possible to generate potent painkillers to help patients cope with chronic pain.”

Professor Bruno Frenguelli, principal investigator on the project, from the University of Warwick’s School of Life Sciences, said, “This is a fantastic example of serendipity in science. We had no expectations that BnOCPA would behave any differently from other molecules in its class, but the more we looked into BnOCPA we discovered properties that had never been seen before, and which may open up new areas of medicinal chemistry.”

Source: Read Full Article